Filter By Industry
Filter By Tag


BiondVax Press releases

1 - 10 of 11 Press Releases

Aug 30, 2011
BiondVax Announces Receipt of IRB Ethics (“Helsinki”) Committee Approvals for the Initiation of Second Phase II Clinical Trial for Universal Influenza Vaccine. The trial will start in October 2011 with 120 participants over the age of 65.

May 31, 2011
BiondVax Pharmaceuticals Ltd. is pleased to announce that the company's Chief Scientific Officer, Dr. Tamar Ben-Yedidia, will present the results of the Phase IIa clinical trial on the universal flu vaccine at the 2011 BIO International Convention.

Nov 10, 2010
BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company developing a Universal Influenza Vaccine, today announced that it has raised $1.25 million under its Standby Equity Distribution Agreement (SEDA) with YA Global Investments L.P.

Nov 04, 2010
Dr. Tamar Ben-Yedidia will be presenting at the Influenza Congress USA next week in Washington, D.C. BiondVax is currently in Phase IIa clinical trials (human subjects) for its Universal Influenza Vaccine.

Sep 28, 2010
Dr. Tamar Ben-Yedidia will be speaking at the upcoming World Vaccine Congress in Lyon, France on October 4, 2010. She will be updating the congress on the company's progress and upcoming Phase II trials starting in October.

Aug 17, 2010
BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine

Jul 28, 2010
According to Frost & Sullivan, BiondVax is the leading company in the quest for the universal influenza vaccine and has received Frost & Sullivan’s 2010 European Influenza Vaccines Technology Innovation Award.

Jun 14, 2010
Chief Scientific Officer, Dr. Tamar Ben Yedidia, will provide an overview of the Company's technology and clinical development progress at two upcoming biopharma industry conferences in Israel and Barcelona, Spain

Jun 09, 2010
BiondVax receives funding based on their work on a Universal Flu Vaccine, receiving an additional $1 Million of funding from the Israel Chief Scientist’s office and signing of the final agreement with Yorkville Advisors for $7m

Mar 09, 2010
BiondVax Reports Positive Interim Safety Results from Second Phase I/II Universal Influenza Vaccine Trial BiondVax’s Multimeric-001 Universal Flu Vaccine Shown to be Safe and Well Tolerated in trial of 60 elderly participants

Page: 1 2 Next
BiondVax RSS Feed